A detailed history of Wells Fargo & Company transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 27,304 shares of ZNTL stock, worth $81,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,304
Previous 28,076 2.75%
Holding current value
$81,912
Previous $114,000 12.28%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.9 - $4.57 $2,238 - $3,528
-772 Reduced 2.75%
27,304 $100,000
Q2 2024

Aug 13, 2024

BUY
$4.09 - $16.13 $32,699 - $128,959
7,995 Added 39.81%
28,076 $114,000
Q1 2024

May 10, 2024

BUY
$10.83 - $16.49 $17,707 - $26,961
1,635 Added 8.86%
20,081 $316,000
Q4 2023

Feb 09, 2024

SELL
$9.84 - $20.13 $313,256 - $640,838
-31,835 Reduced 63.31%
18,446 $279,000
Q3 2023

Nov 13, 2023

SELL
$19.63 - $28.29 $294,842 - $424,915
-15,020 Reduced 23.0%
50,281 $1.01 Million
Q2 2023

Aug 15, 2023

BUY
$17.41 - $30.05 $322,851 - $557,247
18,544 Added 39.66%
65,301 $1.84 Million
Q1 2023

May 12, 2023

BUY
$16.14 - $24.94 $704,042 - $1.09 Million
43,621 Added 1390.98%
46,757 $804,000
Q4 2022

Feb 13, 2023

SELL
$18.07 - $25.6 $45,771 - $64,844
-2,533 Reduced 44.68%
3,136 $63,000
Q3 2022

Nov 14, 2022

SELL
$20.23 - $31.73 $825,667 - $1.3 Million
-40,814 Reduced 87.8%
5,669 $122,000
Q2 2022

Aug 12, 2022

SELL
$17.91 - $52.25 $1.47 Million - $4.28 Million
-81,935 Reduced 63.8%
46,483 $1.31 Million
Q1 2022

May 16, 2022

SELL
$41.58 - $80.89 $64,947 - $126,350
-1,562 Reduced 1.2%
128,418 $5.92 Million
Q4 2021

Feb 14, 2022

SELL
$66.92 - $84.79 $24.5 Million - $31 Million
-365,751 Reduced 73.78%
129,980 $10.9 Million
Q3 2021

Nov 15, 2021

SELL
$46.83 - $73.5 $536,905 - $842,677
-11,465 Reduced 2.26%
495,731 $33 Million
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $18.8 Million - $31.3 Million
503,339 Added 13050.01%
507,196 $27 Million
Q1 2021

May 13, 2021

SELL
$35.69 - $52.72 $464,255 - $685,781
-13,008 Reduced 77.13%
3,857 $167,000
Q4 2020

Feb 09, 2021

BUY
$31.71 - $57.97 $266,839 - $487,817
8,415 Added 99.59%
16,865 $876,000
Q3 2020

Nov 05, 2020

BUY
$27.03 - $47.97 $86,631 - $153,743
3,205 Added 61.11%
8,450 $276,000
Q2 2020

Aug 13, 2020

BUY
$23.2 - $54.8 $121,684 - $287,426
5,245 New
5,245 $252,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.